S
Stephen T. Keir
Researcher at Duke University
Publications - 189
Citations - 14212
Stephen T. Keir is an academic researcher from Duke University. The author has contributed to research in topics: Glioma & In vivo. The author has an hindex of 51, co-authored 180 publications receiving 13036 citations. Previous affiliations of Stephen T. Keir include Howard Hughes Medical Institute & Durham University.
Papers
More filters
Journal ArticleDOI
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
D. Williams Parsons,Siân Jones,Xiaosong Zhang,Jimmy Lin,Rebecca J. Leary,Philipp Angenendt,Parminder Mankoo,Hannah Carter,I-Mei Siu,Gary L. Gallia,Alessandro Olivi,Roger E. McLendon,B.K. Ahmed Rasheed,Stephen T. Keir,Tatiana Nikolskaya,Yuri Nikolsky,Dana A. Busam,Hanna Tekleab,Luis A. Diaz,James Hartigan,Doug R. Smith,Robert L. Strausberg,Suely Kazue Nagahashi Marie,Sueli Mieko Oba Shinjo,Hai Yan,Gregory J. Riggins,Darell D. Bigner,Rachel Karchin,Nick Papadopoulos,Giovanni Parmigiani,Bert Vogelstein,Victor E. Velculescu,Kenneth W. Kinzler +32 more
TL;DR: Recurrent mutations in the active site of isocitrate dehydrogenase 1 (IDH1) occurred in a large fraction of young patients and in most patients with secondary GBMs and were associated with an increase in overall survival.
Journal ArticleDOI
The Genetic Landscape of the Childhood Cancer Medulloblastoma
D. Williams Parsons,D. Williams Parsons,Meng Li,Xiaosong Zhang,Siân Jones,Rebecca J. Leary,Jimmy Lin,Simina M. Boca,Hannah Carter,Josue Samayoa,Chetan Bettegowda,Chetan Bettegowda,Gary L. Gallia,George I. Jallo,Zev A. Binder,Yuri Nikolsky,James Hartigan,Doug R. Smith,Daniela S. Gerhard,Daniel W. Fults,Scott R. VandenBerg,Mitchel S. Berger,Suely Kazue Nagahashi Marie,Sueli Mieko Oba Shinjo,Carlos Clara,Peter C. Phillips,Jane E. Minturn,Jaclyn A. Biegel,Alexander R. Judkins,Adam C. Resnick,Phillip B. Storm,Tom Curran,Yiping He,B.K. Ahmed Rasheed,Henry S. Friedman,Stephen T. Keir,Roger E. McLendon,Paul A. Northcott,Michael D. Taylor,Peter C. Burger,Gregory J. Riggins,Gregory J. Riggins,Rachel Karchin,Giovanni Parmigiani,Darell D. Bigner,Hai Yan,Nick Papadopoulos,Bert Vogelstein,Kenneth W. Kinzler,Victor E. Velculescu +49 more
TL;DR: Key differences between the genetic landscapes of adult and childhood cancers are demonstrated, dysregulation of developmental pathways as an important mechanism underlying MBs is highlighted, and a role for a specific type of histone methylation in human tumorigenesis is identified.
Journal ArticleDOI
The integrated landscape of driver genomic alterations in glioblastoma
Veronique Frattini,Vladimir Trifonov,Joseph M. Chan,Angelica Castano,Marie Lia,Francesco Abate,Francesco Abate,Stephen T. Keir,Alan X. Ji,Pietro Zoppoli,Francesco Niola,Francesco Niola,Carla Danussi,Igor Dolgalev,Paola Porrati,Serena Pellegatta,Adriana Heguy,Gaurav Gupta,David J. Pisapia,Peter Canoll,Jeffrey N. Bruce,Roger E. McLendon,Hai Yan,Kenneth Aldape,Gaetano Finocchiaro,Tom Mikkelsen,Gilbert G. Privé,Gilbert G. Privé,Darell D. Bigner,Anna Lasorella,Raul Rabadan,Antonio Iavarone +31 more
TL;DR: A computational platform that integrates the analysis of copy number variations and somatic mutations and unravels the landscape of in-frame gene fusions in glioblastoma provides insights into the pathogenesis of gliOBlastoma and highlights new targets for therapeutic intervention.
Journal ArticleDOI
The pediatric preclinical testing program: description of models and early testing results.
Peter J. Houghton,Christopher L. Morton,Chandra Tucker,Debbie Payne,Edward Favours,Claire Cole,Richard Gorlick,E. Anders Kolb,Wendong Zhang,Richard B. Lock,Hernan Carol,Mimi Tajbakhsh,C. Patrick Reynolds,John M. Maris,Joshua Courtright,Stephen T. Keir,Henry S. Friedman,Charles M. Stopford,Joseph Zeidner,Jianrong Wu,Tiebin Liu,Catherine A. Billups,Javed Khan,Sherry S Ansher,Jian Zhang,Malcolm A. Smith +25 more
TL;DR: The characteristics of the in vivo tumor panels are described and results for the in vitro evaluation of two standard agents, vincristine and cyclophosphamide are reported.
Journal Article
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.
Ranjit K. Goudar,Qing Shi,Mark D. Hjelmeland,Stephen T. Keir,Roger E. McLendon,Carol J. Wikstrand,Elizabeth D. Reese,Charles A. Conrad,Peter Traxler,Heidi Lane,David A. Reardon,Webster K. Cavenee,Xiao-Fan Wang,Darell D. Bigner,Henry S. Friedman,Jeremy N. Rich +15 more
TL;DR: Combined AEE788 and RAD001 given orally to athymic mice bearing established human malignant glioma tumor xenografts resulted in greater tumor growth inhibition and greater increases in median survival than monotherapy, suggesting that simultaneous inhibition of growth factor receptor and mTOR pathways offer increased benefit in gliomas therapy.